BETAVERT PILLS 24MG

Packaging

30 pieces

Mechanism of action

Betavert is a synthetic analogue of histamine.

Pharmacodynamics

Betahistine acts mainly on the histamine H1 and H3 receptors of the inner ear and the vestibular nuclei of the CNS. Through direct agonistic action on the H1 receptors of the vessels of the inner ear, as well as indirectly through the impact on the H3 receptors, improves microcirculation and permeability of the capillaries of the inner ear, normalizes the pressure of the endolymph in the maze and cochlea. However, betahistine increases blood flow in the basilar artery.
It has a pronounced central effect, being an inhibitor of the H3 receptors of the nuclei of the vestibular nerve. Normalizes conduction in neurons of the vestibular nuclei at the level of the brain stem.
The clinical manifestation of these properties is to reduce the frequency and intensity of dizziness, reduce tinnitus, improve hearing in case of a decrease.

Pharmacokinetics

Rapidly absorbed, low plasma protein binding. The time to reach Cmax is 3 hours. It is almost completely excreted by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours. T1 / 2 - 3-4 hours.

Indications of the drug Betavert

• Treatment and prevention of vestibular vertigo of various origins.
• Syndromes characterized by dizziness, headache, tinnitus, progressive hearing loss, nausea and vomiting.
• Disease and Meniere's syndrome.

Contraindications drug Betavert

• Pregnancy.
• Lactation period (breastfeeding).
• Hypersensitivity to the drug.
With caution: Betavert should be prescribed to patients with gastric ulcer or duodenal ulcer (including a history), patients with pheochromocytoma and bronchial asthma.

Use during pregnancy and lactation

There is not enough data to assess the effects of Betavert during pregnancy and lactation, so its use in these periods is contraindicated.

Special notes

During the period of use of the drug Betavert, patients with gastric ulcer or duodenal ulcer, with pheochromocytoma, with bronchial asthma should be under medical supervision.
Influence on ability to drive motor transport and control mechanisms
Betavert has no sedative effect and does not affect the ability to drive vehicles or work with mechanisms.

Composition

1 pill contains:
Active ingredient: betahistine dihydrochloride - 24 mg.
Excipients: microcrystalline cellulose, lactose (milk sugar), corn starch, polyvinylpyrrolidone (povidone), sodium carboxymethyl starch (primogel), talc, colloidal silicon dioxide (aerosil).

Dosage and administration of the drug Betavert

Betavert drug is prescribed inside during the meal.
Dose / frequency of administration:
• Betavert 8 mg - 1-2 pills 3 times a day.
• Betavert 16 mg - 1 / 2-1 pill 3 times a day.
Improvement of the state is noted already at the beginning of therapy. A stable therapeutic effect is achieved within 2 weeks of taking Betavert and may increase when taking the drug over several months.
The duration of therapy is determined individually.

Side effects

Possible: violations of the gastrointestinal tract.
In very rare cases: skin manifestations of allergic reactions (skin rash, itching, urticaria), angioedema.

Drug interaction

Drug interaction of the drug Betavert with other drugs is not described. Cases of incompatibility are unknown.

Overdosage

Symptoms: nausea, vomiting; when taken in a dose of more than 640 mg, seizures may occur.
Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.

Storage conditions

Betavert should be stored in a dry, dark place, out of reach of children at a temperature not exceeding 25 ° C.